Tuesday, August 02, 2022 11:15:17 AM
Vandana Singh
Mon, August 1, 2022
HC Wainwright initiated coverage on Belite Bio Inc (NASDAQ: BLTE) with a Buy rating and price target of $58 per ADS.
Belite Bio is focused on developing a novel once-daily oral drug for the treatment of Stargardt disease (STGD1)—a rare inherited juvenile-onset form of macular degeneration.
The lead drug candidate is LBS-008 (or Tinlarebant).
HC Wainwright says that as LBS-008 is administered orally once a day, it could be adopted rapidly by ophthalmologists and patients once the drug obtains regulatory approval, as the intravitreal injection procedure was found unpleasant.
"We believe LBS-008 has the potential to be developed as the first and best-in-class oral drug for the treatment of STGD1," the analyst writes.
The analyst expects the Phase 2 portion to report 1-year data in 2H22.
Meanwhile, the company has initiated a Phase 3 trial of LBS-008 in adolescent STGD1 in 1H22, slated to enroll approximately 60 patients. Enrollment for Phase 3 trial to complete in mid-2023.
Successful Trading is the art of minimizing long term risk and maximizing capital allocation.
Recent BLTE News
- Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting • GlobeNewswire Inc. • 05/01/2024 08:15:00 PM
- Belite Bio Announces $25 Million Registered Direct Offering • GlobeNewswire Inc. • 04/25/2024 11:15:29 PM
- Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan • GlobeNewswire Inc. • 03/22/2024 12:00:00 PM
- Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website • GlobeNewswire Inc. • 03/12/2024 02:28:39 AM
- Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/12/2024 01:27:47 AM
- Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results • GlobeNewswire Inc. • 03/06/2024 01:00:00 PM
- Belite Bio to Participate in the Leerink Partners Global Biopharma Conference • GlobeNewswire Inc. • 03/04/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/13/2024 02:08:25 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/13/2024 01:40:46 AM
- Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/07/2024 01:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/28/2023 09:16:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/28/2023 09:15:43 PM
- Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference • GlobeNewswire Inc. • 11/30/2023 01:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/28/2023 10:16:51 PM
- Belite Bio to Participate in the BTIG Ophthalmology Day • GlobeNewswire Inc. • 11/20/2023 01:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/16/2023 09:41:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/16/2023 09:36:52 PM
- Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results • GlobeNewswire Inc. • 11/14/2023 01:15:47 AM
- Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing • GlobeNewswire Inc. • 11/10/2023 01:35:00 PM
- Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/07/2023 01:00:00 PM
- Belite Bio, Inc. to present at the Deutsche Bank ADR Virtual Investor Conference on 8 November 2023 • GlobeNewswire Inc. • 11/06/2023 09:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/06/2023 01:00:06 PM
- Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting • GlobeNewswire Inc. • 11/06/2023 01:00:00 PM
- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts • GlobeNewswire Inc. • 11/01/2023 12:35:00 PM
- Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual Meeting • GlobeNewswire Inc. • 10/27/2023 12:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM